GET DAILY SIGNALSPurple Biotech Ltd (PPBT): Examining Its CAPTN-3 Platform and Early-Stage Pipeline
Key Takeaways
- Purple Biotech Ltd (PPBT) is a clinical-stage biotechnology company headquartered in Rehovot, Israel, focused on oncology therapies that target tumor immune evasion and drug resistance.
- The company was formerly known as Kitov Pharma Ltd and adopted the Purple Biotech name in December 2020, with corporate roots dating back to 1968.
- Its pipeline centers on the CAPTN-3 tri-specific antibody platform, alongside earlier clinical candidates CM24 and NT219.
- As a clinical-stage developer, Purple Biotech has no approved products and generates no meaningful revenue, meaning its financial profile is defined by research spending and net losses.
- Purple Biotech maintains a collaboration agreement with Bristol Myers Squibb (BMY) to evaluate CM24 in combination with the PD-1 inhibitor nivolumab.
Company Background
Purple Biotech Ltd develops next-generation oncology therapies designed to help the immune system overcome tumor immune evasion and drug resistance. I follow PPBT mainly for its early-stage antibody platform and pipeline rather than any current sales or earnings. The company has no approved products on the market, so its value is closely tied to advancing candidates through preclinical and clinical development.
Pipeline and Platform Details
Headquartered in Rehovot, Israel, the company’s shares trade on the Nasdaq and Tel Aviv Stock Exchange under the ticker PPBT. Its corporate history stretches back to 1968, and it rebranded from Kitov Pharma Ltd to Purple Biotech in December 2020 to reflect a sharper focus on oncology.
Central to the business is the CAPTN-3 platform, a modular technology for creating tri-specific antibodies that bind multiple targets and activate an anti-tumor immune response. The lead candidate, IM1240, targets the tumor-associated antigen 5T4, while IM1305 targets TROP2. These programs remain largely preclinical, supported by reported data and manufacturing milestones aimed at moving toward clinical testing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader pipeline includes two earlier clinical candidates. CM24 is a humanized monoclonal antibody that blocks CEACAM1 and is under study in a Phase 2 trial for pancreatic ductal adenocarcinoma alongside an anti-PD-1 checkpoint inhibitor. NT219 is a small molecule inhibiting IRS1/2 and STAT3, evaluated in Phase 2 studies for recurrent or metastatic head and neck cancer and colorectal adenocarcinoma. A collaboration with BMY supports evaluation of CM24 with nivolumab and chemotherapy.
With no commercialized products, revenue is effectively nonexistent, and the company relies on equity financing to fund research. Its model hinges on reaching regulatory milestones, partnerships, or licensing deals. The competitive edge lies in the differentiated tri-specific antibody technology, though it operates in a crowded oncology space with larger, better-funded players.
What Draws Attention to PPBT
Investor focus on PPBT centers on the oncology pipeline and platform technology rather than traditional fundamentals. The CAPTN-3 platform offers a potential point of differentiation through its modular design applicable across multiple tumor targets. The collaboration with Bristol Myers Squibb provides external validation and signals interest from a major pharmaceutical partner.
For those seeking long-term growth drivers, relevance comes from the expanding market for cancer immunotherapies and the chance that the platform could produce first-in-class therapies. Preclinical progress, patent allowances, and manufacturing scalability have shaped market perceptions, yet the early-stage pipeline means the financial profile is defined by research spending and recurring net losses.
Key Risks to Consider
Investing in PPBT involves substantial risks common to clinical-stage biotechnology firms. There are no approved products, little or no revenue, and ongoing research must be funded through equity raises that can dilute shareholders. Drug development is uncertain, with candidates potentially failing trials, encountering safety issues, or facing regulatory delays.
Intense competition from larger pharmaceutical and biotechnology companies with greater resources is another factor. A small workforce and reliance on a limited number of early-stage programs create concentration risk, with the outlook heavily dependent on a few candidates and the CAPTN-3 platform. Regulatory requirements, capital access, and potential Nasdaq compliance issues are additional considerations.
My Experience with Tickeron’s AI Screener
In my own research process, I frequently turn to Tickeron’s AI Screener to identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. The platform helps efficiently screen thousands of stocks and ETFs to surface ideas that align with specific strategies. For names like PPBT or oncology-related themes, it provides a structured way to narrow the universe and refine a watchlist.
Conclusion
Purple Biotech Ltd is a small, clinical-stage oncology company built around its CAPTN-3 tri-specific antibody platform and a pipeline that includes CM24 and NT219. Its focus on multi-target antibody engineering for difficult-to-treat, treatment-resistant cancers sets it apart. For investors, it represents high-risk, early-stage exposure to the immunotherapy space, with long-term relevance depending on successful clinical advancement and meaningful anti-tumor activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT's Stochastic Oscillator is sitting in overbought zone for 4 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PPBT's RSI Oscillator exited the oversold zone, 45 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.498). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
Advertisement